tak-901
Small moleculeexperimental
Clinical trial activity
2 trials · 1 clinical orgs · 0 marketing orgs
Phase 1
2
Phase 2
0
Phase 3
0
Phase 4
0
Earliest trial started Mar 1, 2009 (NCT00807677)
Timeline
2000s
- Jan 1, 2009
Earliest Phase 1 Sponsor(trial)
Indications
Studied for
- Leukemia, Lymphocytic, Chronic, B-Cell · Phase 1
- Leukemia, Myelogenous, Chronic, BCR-ABL Positive · Phase 1
- Leukemia, Myeloid, Acute · Phase 1
- Leukemia, Myeloid, Chronic, Atypical, BCR-ABL Negative · Phase 1
- Lymphoma · Phase 1
- Lymphoma, Non-Hodgkin · Phase 1
- Multiple Myeloma · Phase 1
- Myelodysplastic Syndromes · Phase 1
- Neoplasms · Phase 1
- Polycythemia · Phase 1
- Precursor Cell Lymphoblastic Leukemia-Lymphoma · Phase 1
- Primary Myelofibrosis · Phase 1
- Waldenstrom Macroglobulinemia · Phase 1
Mechanism of action
AURKB inhibitor
Potently inhibits multiple kinases.
Chemistry & pharmacology
Loading structure…
SMILES
CCS(=O)(=O)c1cccc(-c2cc(C(=O)NC3CCN(C)CC3)c(C)c3[nH]c4ncc(C)cc4c23)c1- Mol. weight
- 504.66 g/mol
- Lipinski Ro5
- 1 violation(s)
- Rule of 3
- No
- Chirality
- Achiral Molecule
- Inorganic
- No
- Polymer
- No
Oral
No
Parenteral
No
Topical
No
Sources
- ChEMBLCHEMBL3544932 ↗
Also known as
- tak-901
- tak-901
- tak-901
- tak-901
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT00935844 | Phase 1 | Oct 1, 2009 | Millennium Pharmaceuticals |
| NCT00807677 | Phase 1 | Mar 1, 2009 | Millennium Pharmaceuticals |
Showing 2 of 2 trials
Page 1 / 1
Organizations
Research & Development (1)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Millennium Pharmaceuticals | For profit | 2 | 2 | 1 | 2009 |
1 organizations
Page 1 / 1